TOUGHMAC-E combination capsules for maldigestion (digestive enzymes, diastase, pancreatin)
Product Code :
Availability : 11
General information on Japanese TOUGHMAC-E Combination Capsules for maldigestion (digestive enzymes, diastase, pancreatin)
Package details: 600 capsules
Manufacturer: Ono Pharmaceutical Co., Ltd., Japan
Active ingredient: diasmen, diastase, onotease, molsin, bonlase, cellulosin A.P., pancreatin, polypase, onoprose A
Medical effect: TOUGHMAC-E combination capsules are effective for the treatment of maldigestion (stomach heavy feeling, indigestion)
Contraindications and precautions: do not use for pregnant and breastfeeding women. Do not use for patients with a history of hypersensitivity to protein of cow or pig (beef or pork).
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration
For adults, take 1-2 capsules at a time, 2 to 3 times a day after meals. The doctor in charge may adjust the dosage according to age or symptoms.
How effective are TOUGHMAC-E combination capsules from Japan for maldigestion (digestive enzymes, diastase, pancreatin)?
TOUGHMAC-E combination capsules contain pancreatin, diastase and 7 digestive enzymes, including:
- cellulosin A.P.,
- onoprose A
Pancreatin itself is a mixture of various pancreatic enzymes that help to digest starch, protein and fat. Diastase breaks glycogen into smaller sugar units, maltose and glucose. And digestive enzymes promote digestion of carbohydrate, protein, lipid and fiber.
Who should take TOUGHMAC-E combination capsules from Japan?
TOUGHMAC-E combination capsules are effective for the treatment of maldigestion, including stomach heavy feeling and indigestion. A study held by Japanese scientists for 6 years showed that high-dose digestive enzyme treatment with TOUGHMAC-E capsules significantly reduces the risk of onset of nonalcoholic fatty liver disease (K. Yasukawa, A. Shimizu et al. “Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial”. Journal of the American College of Surgeons, 2020, 231(6): pp. 658-669).